Valuation: Fennec Pharmaceuticals Inc.

Market Cap 396M 339M 317M 290M 545M 37.88B 552M 3.75B 1.46B 19.03B 1.49B 1.45B 62.94B P/E 2026 *
35x
P/E 2027 * 11.4x
Enterprise Value 396M 339M 317M 290M 545M 37.88B 552M 3.75B 1.46B 19.03B 1.49B 1.45B 62.94B EV / Sales 2026 *
5.43x
EV / Sales 2027 * 3.84x
Free-Float
80.4%
Yield 2026 *
-
Yield 2027 * -
1 day-0.90%
1 week-8.94%
Current month+11.84%
1 month+8.93%
3 months+13.15%
6 months+28.87%
Current year+46.13%
1 week 15.49
Extreme 15.49
16.38
1 month 13.85
Extreme 13.85
17.64
Current year 7.59
Extreme 7.59
17.64
1 year 7.59
Extreme 7.59
17.64
3 years 5.65
Extreme 5.65
17.64
5 years 4.95
Extreme 4.95
17.64
10 years 0
Extreme 0
18.86
Manager TitleAgeSince
Chief Executive Officer 64 2024-08-15
Director of Finance/CFO 51 2010-01-05
Chief Tech/Sci/R&D Officer 51 2024-10-27
Director TitleAgeSince
Director/Board Member 72 2011-08-24
Chairman 69 2015-12-08
Director/Board Member 70 2016-08-09
Change 5-day change 1-year change 3-year change Capi.($)
-0.90%-8.94% - - 396M
+0.88%+6.38%+76.40%+126.75% 1,119B
+1.07%+3.80%+50.73%+62.78% 651B
+1.20%+6.21%+25.81%+78.74% 468B
+1.02%+5.77%+43.63%+48.43% 374B
+0.85%+4.07%+24.97%+40.58% 302B
+1.26%+6.81%+2.27%+14.41% 259B
+1.88%+5.81%+49.57%+70.53% 238B
+1.59%+2.09%-17.33%-52.62% 208B
+1.87%+5.61%+27.32%+91.38% 181B
Average +1.07%+4.97%+31.49%+53.44% 422.21B
Weighted average by Cap. +1.14%+5.09%+44.26%+72.65%

Financials

2026 *2027 *
Net sales 72.9M 62.45M 58.43M 53.49M 100M 6.98B 102M 690M 269M 3.5B 274M 268M 11.59B 103M 88.36M 82.68M 75.68M 142M 9.87B 144M 977M 381M 4.96B 387M 379M 16.4B
Net income 11.25M 9.63M 9.01M 8.25M 15.48M 1.08B 15.69M 106M 41.53M 541M 42.23M 41.31M 1.79B 35.24M 30.18M 28.24M 25.85M 48.52M 3.37B 49.16M 334M 130M 1.69B 132M 129M 5.6B
Net Debt - -
Logo Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate, PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Employees
35
Date Price Change Volume
26-08-21 $15.49 -0.90% 616
26-08-20 $15.63 -4.58% 400
26-08-19 $16.38 -3.70% 104
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
11.29USD
Average target price
17.67USD
Spread / Average Target
+56.48%

Quarterly revenue - Rate of surprise